Preclinical vaccine efficacy studies are generally limited to certain read out parameters such as assessment of virus titers in swabs and organs, clinical signs, serum antibody titers, and pathological changes. These parameters are not always routinely applied and not always scheduled in a logical standardized way. We used computed tomography (CT) imaging as additional and novel read out parameter in a vaccine efficacy study by quantifying alterations in aerated lung volumes in ferrets challenged with the 2009 pandemic A/H1N1 influenza virus.
Introduction
The field of influenza virus research is in particular an area of new emerging viruses that requires rapid development of animal models needed for pathogenicity studies and assessment of adequate vaccine candidates and antiviral therapies. This was recently illustrated by the emergence of the 2009 pandemic A/H1N1 influenza virus (pH1N1) [1, 2] . Ferrets are being implemented extensively in human influenza virus research. However, influenza virus research is conducted in multiple separate laboratories all with their unique approach how to evaluate vaccine candidates within the ferret challenge model. Substantial differences can be found in all stages and aspects of challenge protocols, study set-ups and read-out parameters. A spectrum of recently published [1, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] infection/challenge protocols showing this diversity is listed in comparison in Table 1 . In addition, obviously, different influenza strains are used as challenge virus instigated by the antigenic nature of the vaccine, or alternatively to evaluate efficacy to a heterologous influenza virus challenge. The routes of infection being intranasal, intratracheal or through virus transmission from experimentally infected and shedding ferrets show considerable differences in implementation and outcomes [13] . Different viral challenge doses are used, whether or not established in preceding dose-finding studies. However, the challenge doses are pivotal in the interpretation of a challenge outcome. Since, a too robust challenge may prove, false negatively, a poor efficacy of a human vaccine candidate in the ferret model, and vice versa. Furthermore, the duration of the challenge read out period varies, as well as the types of samples collected and frequency of sampling. Often the design of a challenge protocol is based on predefined end points and read outs, or may rely on results from historical experiments.
Because of these variations in the assessment of vaccine efficacy, the comparison of the outcomes of vaccine studies may be hampered, therefore a certain way of standardization could prove useful by providing clarity. Recently, we reported that CT-scanning allows quantification and characterisation of influenza-induced pulmonary lesions in living animals [11] . We showed that the pulmonary ground-glass opacities observed by CT scanning corresponded mainly to areas of alveolar oedema, which is a major histological lesion in early influenza-induced pneumonia and can be used to quantify the aerated lung volume (ALV).
The present study was performed to evaluate the immunogenicity and protective efficacy of an adjuvanted inactivated influenza pH1N1 vaccine for intranasal use in the ferret model. A group of six ferrets was intranasally immunised with this vaccine candidate and compared to a second group of six ferrets that received intranasally administered PBS as placebo. These administrations were performed on study days 0, 21 and 42. All animals were subsequently intratracheally challenged with 10 6 median tissue culture infectious dose (TCID 50 ) H1N1 A/The Netherlands/602/2009 virus on study day 70. The animals were monitored for vaccine induced serological and immunological responses and for infection related clinical and virological responses (data will be presented elsewhere). As novel read out parameter CT-scanning was performed 6 days prior, and daily after, virus inoculation on all twelve ferrets to monitor influenza induced lung damage by quantifying alterations in the ALVs. The animals were sacrificed at 4 days post-inoculation (dpi) to evaluate pathological and virological parameters.
Material and methods

Animals
The ferrets (Mustela putorius furo) were females of 8 months of age, seronegative for antibodies against current circulating influenza viruses, and Aleutian disease virus. Housing and handling was performed under biosafety level (BSL)-3 + conditions in negatively pressurized and high efficiency particulate air (HEPA)-filtered biocontainment isolator units, approved by an independent institutional laboratory animal ethics and welfare committee. General injection anaesthesia (ketamine 8 mg/kg and medetomidine-HCl 7.5 g/kg body weight) was applied during handling and scanning.
Immunisation
The animals (n = 6) were immunised three times with a 3 week interval with an adjuvanted inactivated vaccine. 200 l of vaccine was intranasally administered and divided equally over both nostrils. The controls (n = 6) were similarly sham immunised with 200 l PBS intranasally (referred to as placebo).
Challenge virus
All animals were challenged, 4 weeks after the last immunisation, intratracheally with 10 6 median tissue culture infectious dose (TCID 50 ) of the 2009 pandemic influenza virus A/Netherlands/602/2009 (pH1N1) in 3 ml PBS, as described previously [2, 12, 14] . The virus was routinely propagated in MDCK cell cultures and infectious dose determined as described previously [15] , and titres calculated according to the method of Spearman-Karber [16] .
CT-scanning
All animals were scanned on −6, 1, 2, 3, and 4 d.p.i. (see also Table 1 ). A dual-source ultra fast CT-system (Somatom Definition Flash, Siemens Healthcare) was used (temporal resolution: 0.075 s, spatial resolution is 0.33 mm, table speed of 458 mm/s: ferret thorax acquisition time ≈ 0.22 s; enables accurate scanning of living ferrets without the necessity of breath-holding, respiratory gating, or electrocardiogram (ECG)-triggering) as previously described [11] . Briefly, during scanning the ferrets were in dorsal recumbency in a purposely built (Tecnilab-BMI) perspex biosafety container of 8.3 L capacity. The post-infectious reductions in aerated lung volumes were measured from 3-dimensional CT reconstructs using lower and upper thresholds in substance densities of −870 to −430 Hounsfield units (HU).
Pathology
Following euthanasia by exsanguination all animals were submitted for necropsy. The lung lobes were inspected and lesions were assessed while the lung was inflated. The trachea was cut at the level of the bifurcation and the lungs were weighed. The relative lung weight was calculated as proportion of the body weight on day of death (lung weight/body weight × 100). 
Results and discussion
All animals from both groups were scanned 6 days prior to virus inoculation to define the uninfected base-line status of their respiratory system. Consecutive in vivo imaging with CT scanning showed that ferrets intranasally immunised with the vaccine candidate were largely protected against the appearance of pulmonary ground-glass opacities, as is shown by means of transversal CT images in Fig. 1 . The ALVs measured from 3D CT reconstructs likewise showed that the immunised ferrets were protected against major alterations in ALV (group mean ALV ranging from 0.95 to −7.8%) and did not show a temporal increase in ALV on 1 dpi, which was observed in the placebo group (group mean ALV ranging from 17.3 to −14.3%) (Fig. 2) . This sudden and short increase of 17.3% (Mann-Whitney test, two-tailed, P = 0.035) in the unprotected placebo-treated animals may result from a virally-induced acute respiratory depression with compensatory hyperinflation. A compensatory increase in respiratory tidal volume by means of hyperinflation is a pathophysiological phenomenon known to occur in respiratory viral infections [17, 18] . However, CT scanning could not discern possible emphysema due to ruptured alveoli as cause of ALV increase. The relative change of ALVs on days 2, 3 and especially 4 after infection did not show significant differences between the two groups. One possible explanation is that overexpansion of the thorax and lungs allows for increased alveolar flooding in excess of base line aeration resulting in approximately unaltered ALVs between the two groups. Another explanation is that the inflamed and oedematous areas were aerated less than normal, but because the unaffected areas of lung were aerated more Nevertheless, these ALV profiles provide more detailed knowledge about the influenza-induced respiratory disease development than confined data obtained from a single predefined read out. Moreover, survival and recovery from challenge infection can be included in this set-up and with the opportunity to still measure the development of serum antibody responses upon challenge infection.
Upon necropsy, the relative lung weights (RLWs) of the intranasally immunised ferrets was about 2-fold lower (Mann-Whitney, two-tailed, P < 0.0047) as compared to those of the placebo-treated animals (Fig. 3) , which is in agreement with the absence of pulmonary ground-glass opacities. Usually, more severely affected and inflamed lungs with increased amounts of fluid are heavier compared to normal or less affected lungs. This translates within the ferret model in influenza research to RLWs ≤ 1.0 associated with non-to minimally affected lungs and RLWs > 1.0 associated with severe pulmonary inflammation with oedema [12, 19, 20] .
In conclusion, the implementation of consecutive CT imaging enables repeated in vivo measurements of lung aeration as parameter to evaluate vaccine efficacy in preclinical protocols. Consecutive day to day imaging overcomes the limitations entailed by necropsy at a predefined time point after infection, and the lung capacity can be repeatedly quantified in real-time.
